CRL

Charles River Laboratories is a leading contract research organization providing preclinical and research-model services (its DSA, RMS and Manufacturing segments) to drug developers across more than a dozen countries. The headline FY2025 figures look alarming — a net loss of -$144M, -$2.91 diluted EPS and a -63.6x P/E — but they are heavily distorted by non-cash items. Operating income remained positive at $25.2M, depreciation and amortization rose 11.5% to $403M, and the 10-K's Restructuring and Asset Impairments note points to impairment and restructuring charges as the driver of the loss. Tellingly, operating cash flow was essentially flat at a robust $738M, confirming the underlying business still generates substantial cash.

The real concern is growth, not solvency. Revenue slipped 0.9% to $4.02B and has now plateaued around $4B for three straight years (from $4.13B in 2023), reflecting pressure on biopharma R&D budgets that drive demand for outsourced research. Net income has collapsed from $475M (2023) to $22.2M (2024) to a loss in 2025 — a steep deterioration in reported profitability even allowing for impairments. The company is responding by deleveraging modestly and returning cash aggressively, with buybacks up 202.6% to $361M and shares down 3.7%.